Clinical Trial Reports Omalizumab Associated with Improvement in Lupus (SLE) Disease Activity

Very early research of omalizumab (known as Xolair®), currently used for the treatment of asthma, shows the drug was well tolerated in people with systemic lupus erythematosus (SLE) and associated with improvement in disease activity. Larger randomized clinical trials are needed to assess efficacy for people with lupus. Continue to follow the Lupus Foundation of America for updates on omalizumab.